TY - JOUR
KW - alternatives to animal testing
KW - Drug development
KW - microphysiological systems
KW - organ-on-a-chip
KW - organoid
AU - Hiroshi Kimura
AU - Masaki Nishikawa
AU - Naokata Kutsuzawa
AU - Fumiya Tokito
AU - Takuma Kobayashi
AU - Dhimas Agung Kurniawan
AU - Hiroki Shioda
AU - Wenxin Cao
AU - Kenta Shinha
AU - Hiroko Nakamura
AU - Kotaro Doi
AU - Yasuyuki Sakai
AB - This study explored the evolving landscape of Microphysiological Systems (MPS), with a focus on organoids and organ-on-a-chip (OoC) technologies, which are promising alternatives to animal testing in drug discovery. MPS technology offers in vitro models with high physiological relevance, simulating organ function for pharmacokinetic studies. Organoids composed of 3D cell aggregates and OoCs mimicking in vivo environments based on microfluidic platforms represent the forefront of MPS. This paper provides a comprehensive overview of their application in studying the gut, liver, and kidney and their challenges in becoming reliable alternatives to in vivo models. Although MPS technology is not yet fully comparable to in vivo systems, its continued development, aided by in silico, automation, and AI approaches, is anticipated to bring about further advancements. Collaboration across multiple disciplines and ongoing regulatory discussions will be crucial in driving MPS toward practical and ethical applications in biomedical research and drug development.
BT - Drug Metabolism and Pharmacokinetics
DA - 2025-02-01
DO - 10.1016/j.dmpk.2024.101046
N2 - This study explored the evolving landscape of Microphysiological Systems (MPS), with a focus on organoids and organ-on-a-chip (OoC) technologies, which are promising alternatives to animal testing in drug discovery. MPS technology offers in vitro models with high physiological relevance, simulating organ function for pharmacokinetic studies. Organoids composed of 3D cell aggregates and OoCs mimicking in vivo environments based on microfluidic platforms represent the forefront of MPS. This paper provides a comprehensive overview of their application in studying the gut, liver, and kidney and their challenges in becoming reliable alternatives to in vivo models. Although MPS technology is not yet fully comparable to in vivo systems, its continued development, aided by in silico, automation, and AI approaches, is anticipated to bring about further advancements. Collaboration across multiple disciplines and ongoing regulatory discussions will be crucial in driving MPS toward practical and ethical applications in biomedical research and drug development.
PY - 2025
EP - 101046
ST - Advancements in Microphysiological systems
T2 - Drug Metabolism and Pharmacokinetics
TI - Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs-
UR - https://www.sciencedirect.com/science/article/pii/S1347436724000521
VL - 60
Y2 - 2025-01-27
SN - 1347-4367
ER -